Patrick Glover

Patrick Glover

Auto-generated profile, based on publicly available information

Patrick Glover

Department of Neurology, Emory University, Atlanta, GA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
OLOswaldo Lorenzo-Betancor
Oswaldo Lorenzo-Betancor
PBPatrick Blackburn
Patrick Blackburn
EEEmily Edwards
Emily Edwards
RVRocío Vázquez-Do-Campo
Rocío Vázquez-Do-Campo
EKEric W. Klee
Eric W. Klee
OROwen A Ross
Owen A Ross
Objective To identify novel genes involved in the etiology of intracranial aneurysms (IAs) or subarachnoid hemorrhages (SAHs) using whole-exome sequencing. Methods We performed whole-exome sequencing in 13 individuals from 3 families with an autosomal dominant IA/SAH inheritance pattern to look for candidate genes for disease. In addition, we sequenced PCNT exon 38 in a further 161 idiopathic patients with IA/SAH to find additional carriers of potential pathogenic variants. Results We identified 2 different variants in exon 38 from the PCNT gene shared between affected members from 2 different families with either IA or SAH (p.R2728C and p.V2811L). One hundred sixty-four samples with either SAH or IA were Sanger sequenced for the PCNT exon 38. Five additional missense mutations were identified. We also found a second p.V2811L carrier in a family with a history of neurovascular diseases. Conclusion The PCNT gene encodes a protein that is involved in the process of microtubule nucleation and organization in interphase and mitosis. Biallelic loss-of-function mutations in PCNT cause a form of primordial dwarfism (microcephalic osteodysplastic primordial dwarfism type II), and ≈50% of these patients will develop neurovascular abnormalities, including IAs and SAHs. In addition, a complete Pcnt knockout mouse model (Pcnt−/−) published previously showed general vascular abnormalities, including intracranial hemorrhage. The variants in our families lie in the highly conserved PCNT protein-protein interaction domain, making PCNT a highly plausible candidate gene in cerebrovascular disease.

12 August 2025 in Neurology
Verified
Journal Article
Closed access
JSJames E. Siegler
James E. Siegler
EGElena Badillo Goicoechea
Elena Badillo Goicoechea
MPMary Penckofer
Mary Penckofer
KEKelsey Eklund
Kelsey Eklund
SYShadi Yaghi
Shadi Yaghi
JTJesse Thon
Jesse Thon
Embolic stroke of undetermined source (ESUS) can be attributed to a variety of potential embolic sources, with differential response to anticoagulation. A multicenter, retrospective observational cohort study (27 sites) of consecutive adult patients with acute ischemic stroke due to ESUS (admitted 2015-2024) was conducted. The aim was to compare outcomes after antiplatelet(s) vs anticoagulant (±antiplatelet) treatment in patients with ESUS across potential embolic sources. The time from admission to the primary composite outcome of recurrent stroke, major bleeding, or death was assessed using adjusted Cox proportional hazard regression (clustered by site) and propensity score (PS) matching with (1) inverse probability of treatment weighting (IPTW) and (2) 10:1 nearest-neighbor matching with replacement, adjusting for age, stroke severity, and potential embolic sources (e.g., left ventricular injury and patent foramen ovale). Recurrent stroke, major bleeding, and death were also assessed as secondary outcomes, with stratification by potential embolic sources. Of the 2,328 included patients (n = 230 treated with anticoagulation), the median age was 65 years (interquartile range [IQR] 54-75), 50% were female, and the median NIH Stroke Scale score was 4 (IQR 2-11). Compared with patients treated using antiplatelet(s) therapies, those treated with anticoagulants were not at a lower risk of the primary outcome in the adjusted Cox model (adjusted hazard ratio [aHR] 1.00, 95% CI 0.69-1.45), adjusted IPTW regression model (aHR 1.15, 95% CI 0.79-1.66), or 10:1 PS-matched regression model (aHR 1.00, 95% CI 0.70-1.44). In patients with left ventricular injury, anticoagulation was associated with a lower rate of the primary outcome (aHR 0.35, 95% CI 0.16-0.77; p-interaction <0.01) and trended toward a lower rate of recurrent ischemic stroke (aHR 0.22, 95% CI 0.05-1.08; p-interaction = 0.04) when compared with patients treated with antiplatelet(s). These real-world data validate randomized trial results in ESUS, which reported no net benefit of anticoagulation over antiplatelet therapy. These data suggest possible benefit of anticoagulation in patients with left ventricular injury, as in previous cohort studies, although the findings are limited by the small number of patients treated with anticoagulation. Future trials should evaluate treatment differences in this subgroup. Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence; registration ID: NCT06398366. Registered on May 3, 2024. This study provides Class III evidence that in patients with ESUS, anticoagulation was not superior to antiplatelet therapy in reducing the risk of recurrent stroke, bleeding, or death.

1 August 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
HAHassan Aboul-Nour
Hassan Aboul-Nour
JSJames E. Siegler
James E. Siegler
STSean L. Thompson
Sean L. Thompson
PGPatrick A. Glover
Patrick A. Glover
JDJean-Philippe Auguste Daniel
Jean-Philippe Auguste Daniel
FNFadi Nahab
Fadi Nahab
Background and ObjectivesMultiple clinical trials have failed to show benefit of anticoagulation over antiplatelets in preventing recurrent stroke among patients with embolic stroke of undetermined...